Skip to main content

Research Repository

Advanced Search

Reconstruction of the historic time course of blood‐borne virus contamination of clotting factor concentrates, 1974–1992

McClure, C. Patrick; Kean, Kai; Reid, Kaitlin; Mayne, Richard; Fu, Michael X.; Rajendra, Piya; Gates, Shannah; Breuer, Judy; Harvala, Heli; Golubchik, Tanya; Tarr, Alexander W.; Irving, William L.; Makris, Michael; Simmonds, Peter

Reconstruction of the historic time course of blood‐borne virus contamination of clotting factor concentrates, 1974–1992 Thumbnail


Authors

Kai Kean

Kaitlin Reid

Richard Mayne

Michael X. Fu

Piya Rajendra

Shannah Gates

Judy Breuer

Heli Harvala

Tanya Golubchik

Michael Makris

Peter Simmonds



Abstract

Factor VIII and IX clotting factor concentrates manufactured from pooled plasma have been identified as potent sources of virus infection in persons with hemophilia (PWHs) in the 1970s and 1980s. To investigate the range and diversity of viruses over this period, we analysed 24 clotting factor concentrates for several blood-borne viruses. Nucleic acid was extracted from 14 commercially produced clotting factors and 10 from nonremunerated donors, preserved in lyophilized form (expiry dates: 1974–1992). Clotting factors were tested by commercial and in-house quantitative PCRs for blood-borne viruses hepatitis A, B, C and E viruses (HAV, HBV, HCV, HEV), HIV- types 1/2, parvoviruses B19V and PARV4, and human pegiviruses types 1 and 2 (HPgV-1,-2). HCV and HPgV-1 were the most frequently detected viruses (both 14/24 tested) primarily in commercial clotting factors, with frequently extremely high viral loads in the late 1970s–1985 and a diverse range of HCV genotypes. Detection frequencies sharply declined following introduction of virus inactivation. HIV-1, HBV, and HAV were less frequently detected (3/24, 1/24, and 1/24 respectively); none were positive for HEV. Contrastingly, B19V and PARV4 were detected throughout the study period, even after introduction of dry heat treatment, consistent with ongoing documented transmission to PWHs into the early 1990s. While hemophilia treatment is now largely based on recombinant factor VIII/IX in the UK and elsewhere, the comprehensive screen of historical plasma-derived clotting factors reveals extensive exposure of PWHs to blood-borne viruses throughout 1970s-early 1990s, and the epidemiological and manufacturing parameters that influenced clotting factor contamination.

Journal Article Type Article
Acceptance Date Jun 21, 2024
Online Publication Date Jul 2, 2024
Publication Date 2024-07
Deposit Date Jul 12, 2024
Publicly Available Date Jul 12, 2024
Journal Journal of Medical Virology
Print ISSN 0146-6615
Electronic ISSN 1096-9071
Publisher Wiley
Peer Reviewed Peer Reviewed
Volume 96
Issue 7
Article Number e29774
DOI https://doi.org/10.1002/jmv.29774
Public URL https://nottingham-repository.worktribe.com/output/36877160
Publisher URL https://onlinelibrary.wiley.com/doi/10.1002/jmv.29774

Files





You might also like



Downloadable Citations